ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for alerts Register for real-time alerts, custom portfolio, and market movers

ODX Omega Diagnostics Group Plc

2.20
0.00 (0.00%)
19 Apr 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Type Share ISIN Share Description
Omega Diagnostics Group Plc LSE:ODX London Ordinary Share GB00B1VCP282 ORD 4P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.00 0.00% 2.20 2.00 2.40 0.00 01:00:00
Industry Sector Turnover Profit EPS - Basic PE Ratio Market Cap
0 0 N/A 0

Omega Diagnostics Group PLC Allergy CE-Mark and first Purchase Order (0735C)

27/09/2018 7:00am

UK Regulatory


Omega Diagnostics (LSE:ODX)
Historical Stock Chart


From Apr 2019 to Apr 2024

Click Here for more Omega Diagnostics Charts.

TIDMODX

RNS Number : 0735C

Omega Diagnostics Group PLC

27 September 2018

Omega Diagnostics Group PLC

("Omega" or the "Company")

Allergy CE-Mark and first Purchase Order

Omega (AIM: ODX), the medical diagnostics company focused on allergy, food intolerance and infectious disease, announces that it has CE-Marked five additional allergens, extending the menu to 58 allergens which can be run on the fully automated IDS Instrument.

These allergens will be supplied to IDS under the global distribution agreement announced on 20 April 2018. Ongoing investment to increase the menu is supported by the research and development grant of up to GBP1.8 million, which the Company secured from Scottish Enterprise in August 2016.

The Company also confirms that commercialisation activities with IDS are proceeding to plan and that it has received its first purchase order which it will supply by the end of October. The size of the order is in line with the Company's expectation, whereby sales are expected to be modest during the initial launch phase.

Contacts:

 
 Omega Diagnostics Group PLC                                    Tel: 01259 763 030 
 Colin King, Chief Executive                              www.omegadiagnostics.com 
 Kieron Harbinson, Group Finance 
  Director 
 
 finnCap Ltd                                                    Tel: 020 7220 0500 
 Geoff Nash/James Thompson (Corporate 
  Finance) 
 Camille Gochez (Corporate Broking) 
 
 Walbrook PR Limited                    Tel: 020 7933 8780 or omega@walbrookpr.com 
 Paul McManus                                                   Mob: 07980 541 893 
 Lianne Cawthorne                                               Mob: 07584 391 303 
 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

END

MSCLFMFTMBITBJP

(END) Dow Jones Newswires

September 27, 2018 02:00 ET (06:00 GMT)

1 Year Omega Diagnostics Chart

1 Year Omega Diagnostics Chart

1 Month Omega Diagnostics Chart

1 Month Omega Diagnostics Chart

Your Recent History

Delayed Upgrade Clock